Urgent.News

What's breaking now, across thousands of outlets.

Tech

iPhone Ultra is Apple's biggest product for years, but supply chain issues mean not everyone may get it at launch

Apple's issues producing enough foldable iPhone Ultras may lead to a staggered global release. Here's what we know so far.

iPhone Ultra is Apple's biggest product for years, but supply chain issues mean not everyone may get it at launch

The iPhone Ultra, Apple's most ambitious product in recent years, is set to make a debut at the September Apple Event. Despite its high price tag rumored to be around $2,500, there are concerns about potential supply chain limitations. According to Australian publication ChannelNews, Apple may stagger the release of the iPhone Ultra by country, starting with the U.S. market.

This strategy mirrors Apple's previous approach with the Apple Vision Pro. The delays in the U.S. are attributed to supply and pricing issues, as well as testing problems with already built production models. While some reports claim that the iPhone Ultra may not even be announced, others suggest it could make an appearance alongside the iPhone 18 Pro.

Apple aims to produce around 10 million units, though this is a fraction of the non-folding devices it sells annually. The staggered release could be a strategic move for Apple to push ahead with a late 2026 release without facing production issues. However, the success of the iPhone Ultra will depend on whether demand remains strong, particularly in the U.S. market.

Written by urgent.news from Tom's Guide's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at tomsguide.com →

More in Tech

Stockholm’s Pixelgen Technologies secures €13.26 million to advance spatial mapping of cell-surface proteins

Pixelgen Technologies, a Stockholm-based life sciences company that claims to have developed the first high-throughput platform for mapping molecular cell architecture, has closed an oversubscribed…

  • Stockholm-based life sciences firm Pixelgen Technologies secures €13.26 million in Series B funding.
  • New investors Flat Capital and existing investors Industrifonden and Navigare Ventures participate.
  • Funding will support global expansion and accelerate commercialisation of Proxiome Kit technology.

More from Thursday 20 August →